Back to results
US 8,409,794 B2Granted
Biomarkers useful for diagnosing prostate cancer, and methods thereof
AssigneePhenomenome Discoveries Inc.
InventorsShawn Ritchie, Erin Bingham
Life of this patent
Estimating the term…
Abstract
The present invention describes a method for predicting a health-state indicative of the presence of prostate cancer. The method measures the intensities of specific small biochemicals, called metabolites, in a blood sample from a patient with an undetermined health-state, and compares these intensities to the intensities observed in a population of healthy individuals and/or to the intensities previously observed in a population of confirmed prostate cancer-positive individuals. The method enables a practitioner to determine the probability that a screened patient is positive for prostate cancer.
Claims30
A method for determining prostate cancer, or the risk of prostate cancer in a patient, the method comprising the steps of:
- a) analyzing at least one blood sample from said patient by high resolution mass spectrometry to obtain accurate mass intensity data;
- b) comparing the accurate mass intensity data to corresponding data obtained from one or more than one reference blood sample to identify an increase or decrease in accurate mass intensity;
- and
- c) using said increase or decrease in accurate mass intensity to determine prostate cancer, or the risk of prostate cancer in said patient,
- wherein the accurate mass intensity is measured, in Daltons, at one or more of the following hydrogen and electron adjusted accurate masses or neutral accurate masses ±5 ppm,
- wherein the hydrogen and electron adjusted accurate masses or neutral accurate masses at which intensity decreases are:
- 174.1408, 188.1566, 194.0804, 232.9133, 242.2251, 252.2096, 258.2482, 268.2412, 272.2357, 276.2096, 278.2256, 279.2287, 280.2414, 281.2448, 283.2602, 292.204, 296.2358, 298.2519, 299.2558, 300.2098, 300.2676, 302.2256, 304.2394, 304.241, 305.243, 305.2439, 306.257, 308.2715, 310.2154, 310.2884, 312.2313, 312.304, 314.2464, 320.2358, 326.2262, 327.0326, 329.2426, 329.2445, 330.2568, 340.2977, 342.2198, 368.3437, 369.3474, 371.3538, 392.294, 411.3186, 430.3083, 430.3818, 431.3861, 432.3686, 452.2536, 481.3171, 481.3172, 482.3216, 484.3792, 492.4184, 494.4344, 495.3328, 495.4376, 496.336, 501.2848, 505.3227, 506.3213, 507.3317, 509.3493, 517.3148, 518.3182, 518.4345, 519.332, 519.3328, 520.4502, 521.348, 521.4526, 522.464, 523.364, 523.4678, 524.4725, 529.3167, 531.3123, 534.4645, 538.501, 541.3148, 541.3422, 541.3433, 542.3453, 542.3461, 545.346, 548.4817, 549.4848, 552.4048, 555.3101, 565.3393, 565.3394, 566.3433, 566.3434, 567.3546, 567.3548, 568.3573, 568.3574, 569.3687, 569.3691, 570.3726, 570.4653, 570.4915, 579.5322, 580.5345, 587.3228, 589.3401, 589.3404, 590.343, 590.4597, 596.4794, 599.4932, 601.5077, 604.5441, 605.5469, 609.3242, 612.5004, 615.4797, 622.4973, 623.4918, 623.5003, 624.5134, 625.5078, 625.5163, 626.5109, 626.5285, 627.5204, 627.5306, 628.5236, 628.5426, 629.5453, 630.5582, 632.5752, 635.5246, 641.4915, 646.5709, 647.574, 647.6063, 648.5865, 649.5056, 649.5898, 655.5509, 660.5005, 660.6082, 663.4864, 670.5688, 670.5711, 671.5723, 672.5865, 673.5893, 673.6185, 673.6224, 675.6359, 675.6375, 676.6393, 680.5625, 684.5487, 685.5543, 686.5126, 688.5294, 690.4849, 690.547, 692.5571, 693.611, 695.647, 696.5856, 696.651, 699.5205, 702.5675, 705.6083, 707.6256, 708.6308, 710.4923, 716.4982, 721.6388, 722.6423, 723.5194, 723.5198, 724.5247, 724.5496, 725.5375, 726.5456, 727.5565, 728.562, 729.5724, 731.4913, 732.4938, 733.6425, 735.6555, 736.6584, 737.5354, 738.5449, 741.5307, 742.5354, 743.5469, 744.4942, 745.4972, 746.556, 747.5201, 747.5234, 748.5279, 748.5722, 749.5346, 749.5354, 749.5364, 749.5402, 749.5763, 750.5403, 750.5434, 751.551, 751.5529, 751.5548, 752.5565, 752.5578, 753.5674, 755.4866, 756.4905, 757.5017, 757.5618, 758.5089, 758.5654, 759.516, 759.578, 760.5223, 760.5816, 761.5269, 765.5665, 766.5701, 767.5821, 768.4944, 768.5507, 769.4957, 770.5109, 771.5809, 772.5269, 772.5856, 773.5337, 774.5404, 775.553, 775.5533, 776.5563, 776.6057, 777.5679, 779.5438, 779.5831, 780.5474, 781.5612, 782.5087, 782.5649, 783.5141, 783.578, 784.5235, 784.5813, 785.5295, 785.5936, 786.5404, 786.5967, 787.5447, 793.5387, 794.5126, 794.5424, 795.5555, 796.5292, 798.6776, 803.5436, 803.5685, 804.547, 804.5717, 804.7208, 804.7219, 805.5606, 805.5834, 805.7267, 806.5643, 806.5863, 807.5761, 808.5795, 809.5937, 810.5401, 810.597, 811.5733, 812.5767, 813.5888, 814.592, 816.5591, 816.7297, 817.5376, 819.5553, 821.5718, 822.5751, 824.689, 825.5545, 825.5548, 826.5579, 826.7053, 827.5439, 827.5698, 827.5699, 827.7084, 828.5734, 828.5741, 828.7206, 829.5597, 829.5857, 829.7239, 829.7244, 830.5887, 830.6537, 830.7359, 831.575, 831.5999, 831.6002, 831.7409, 832.5765, 832.6028, 832.6039, 835.6996, 836.7063, 837.5884, 837.7182, 838.7227, 839.7321, 847.5955, 850.703, 851.5689, 851.7111, 852.5725, 852.7198, 852.7242, 853.5854, 853.7252, 854.5887, 855.6013, 856.6046, 856.6697, 857.617, 857.6733, 858.6847, 859.6877, 861.5265, 861.7174, 861.7808, 862.7228, 863.6874, 863.7339, 864.738, 865.7482, 866.7527, 867.7576, 871.5528, 872.5556, 873.5684, 876.7223, 877.7271, 878.7381, 879.598, 879.742, 880.7528, 880.7555, 881.7568, 881.7609, 882.7673, 882.7717, 883.7715, 884.7817, 884.7873, 885.7867, 885.7919, 886.5582, 886.8027, 887.5625, 887.8022, 893.774, 894.7273, 894.7813, 895.5578, 895.559, 895.7335, 895.7873, 896.745, 897.573, 897.75, 898.7605, 899.5871, 899.7663, 900.5897, 902.737, 903.7407, 904.7535, 905.7573, 906.769, 907.7735, 908.708, 908.7842, 908.7843, 909.7153, 909.7892, 910.7248, 910.7979, 911.7326, 912.7412, 913.7502, 914.7577, 915.7673, 916.774, 917.7836, 918.7901, 919.7981, 920.747, 920.8054, 921.753, 921.8145, 922.7656, 922.8229, 923.5884, 923.7675, 924.7826, 926.7371, 928.7519, 930.7673, 931.7691, 931.793, 932.7819, 934.7235, 935.7299, 936.7387, 937.7457, 938.7553, 939.7616, 940.7709, 941.7779, 942.7876, 943.7931, 944.8033, 945.8085, 946.8187, 950.7385, 952.7568, 952.7759, 954.7905, 962.7616, 964.7764, 965.7839, 966.7933, 967.7981, 968.8072, 1016.929, 1017.934, 1018.943, 1019.95, 1040.934, 1225.093, 1226.098, 1227.107, 1228.113, 1229.118, 1251.115, and 1253.129, and a decrease in the accurate mass intensity at one or more of said accurate masses in the blood sample from the patient relative to the reference indicates that the patient has prostate cancer or is at risk of prostate cancer;
- and
- wherein the hydrogen and electron adjusted accurate masses or neutral accurate masses at which intensity increases are:
- 202.0454, 205.8867, 216.0401, 218.0372, 226.0687, 228.1476, 243.0719, 244.056, 247.9578, 273.874, 283.9028, 317.9626, 326.2476, 328.2628, 331.8326, 339.9964, 341.8614, 351.8906, 354.1668, 382.2903, 472.3925, 473.3957, 552.3825, 582.2469, 583.2504, 736.2234, 776.6069, 783.6349, 997.3968, 1176.777 and 1373.744, and an increase in the accurate mass intensity at one or more of said accurate masses in the blood sample from the patient relative to the reference indicates that the patient has prostate cancer or is at risk of prostate cancer.
7 more elements
A method for determining prostate cancer, or the risk of prostate cancer in a patient, the method comprising the steps of:
- a) analyzing at least one blood sample from said patient to obtain quantifying data for one or more than one metabolite marker using an analyzer comprising a mass spectrometer;
- b) comparing the quantifying data for said one or more than one metabolite marker to corresponding data obtained for one or more than one reference blood sample to identify a decrease in the level of said one or more than one metabolite marker in said blood sample;
- and
- c) using said decrease in the level of said one or more than one metabolite marker in said at least one sample for determining prostate cancer, or the risk of prostate cancer in said patient,
- wherein the one or more than one metabolite marker comprises one or more lysophospho lipid selected from the group consisting of:
- lysophosphatidylcho lines, lysophosphatidylethanolamines, lysophosphatidyl-dimethylethanolamines, lysophosphatidylserines, lysosphingosylphosphoryl-cholines, lysophosphatidylglycerols, lysophosphatidylinositols, platelet activating factors (PAFs), and combinations thereof,
- and wherein a decrease in the level of said one or more than one metabolite marker in the blood sample from the patient relative to the reference indicates that the patient has prostate cancer or is at risk of prostate cancer.
4 more elements
A method for determining prostate cancer, or the risk of prostate cancer in a patient, the method comprising the steps of:
- a) analyzing at least one blood sample from said patient by high resolution mass spectrometry to obtain accurate mass intensity data;
- b) comparing the accurate mass intensity data to corresponding data obtained from one or more than one reference blood sample to identify an increase or decrease in accurate mass intensity;
- and
- c) using said increase or decrease in accurate mass intensity to determine prostate cancer or the risk of prostate cancer in said patient,
- wherein the accurate mass intensity is measured, in Daltons, at the hydrogen and electron adjusted accurate mass or neutral accurate mass of 519.3328±5 ppm and wherein a decrease in the accurate mass intensity of 519.3328 in the blood sample from the patient relative to a reference blood sample indicates that patient has prostate cancer or is at risk of prostate cancer.
2 more elements
Dependencies are inferred from the claim text.